Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;104(1):107-113.
doi: 10.1111/cge.14327. Epub 2023 Mar 27.

Hereditary cancer predispositions: Comparison of multigene panel sequencing on fresh-frozen breast/ovarian tumor versus blood

Mathias Schwartz  1   2 , Virginie Moncoutier  1   2 , Adrien Peytral  1   2 , Jessica Le Gall  1   2 , Voreak Suybeng  1   2 , Mélanie Pagès  1   2 , Julien Masliah-Planchon  1   2 , Olfa Trabelsi-Grati  1   2 , Samia Melaabi  1   2 , Céline Callens  1   2 , Ivan Bièche  1   3 , Hélène Delhomelle  1   2 , Antoine De Pauw  1   2 , Claire Saule  1   2 , Emmanuelle Mouret-Fourme  1   2 , Marion Gauthier-Villars  1   2 , Bruno Buecher  1   2 , Chrystelle Colas  1   2   4 , Dominique Stoppa-Lyonnet  1   3   4 , Lisa Golmard  1   2
Affiliations

Hereditary cancer predispositions: Comparison of multigene panel sequencing on fresh-frozen breast/ovarian tumor versus blood

Mathias Schwartz et al. Clin Genet. 2023 Jul.

Abstract

In breast or ovarian cancer (BC/OC) patients with evocative personal and/or family history, multigene panel sequencing is performed on blood to diagnose hereditary predispositions. Additionally, BRCA1/BRCA2 testing can be performed on tumor sample for therapeutic purpose. The accuracy of multigene panel tumor analysis on BC/OC to detect predisposing germline pathogenic variants (gPV) has not been precisely assessed. By comparing sequencing data from blood and fresh-frozen tumor we show that tumor genomic instability causes pitfalls to consider when performing tumor testing to detect gPV. Even if loss of heterozygosity increases germline signal in most cases, somatic copy number variants (CNV) can mask germline CNV and collapse point gPV variant allele frequency (VAF). Moreover, VAF does not allow an accurate distinction between germline and somatic pathogenic variants.

Keywords: HBOC; MSH6; PARPi; RAD51C; TP53.

PubMed Disclaimer

References

REFERENCES

    1. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26(7):1291-1299. doi:10.1093/annonc/mdv022
    1. Moretta J, Berthet P, Bonadona V, et al. Recommandations françaises du Groupe Génétique et Cancer pour l'analyse en panel de gènes dans les prédispositions héréditaires au cancer du sein ou de l'ovaire. Bull Cancer (Paris). 2018;105(10):907-917. doi:10.1016/j.bulcan.2018.08.003
    1. Marchetti C, Minucci A, D'Indinosante M, et al. Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach. Gynecol Oncol. 2020;158(3):740-746. doi:10.1016/j.ygyno.2020.06.479
    1. Chandrasekaran D, Sobocan M, Blyuss O, et al. Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: SIGNPOST study. Cancer. 2021;13(17):4344. doi:10.3390/cancers13174344
    1. Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22:1721-1731. doi:10.1016/S1470-2045(21)00531-3